Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KB Kuchenbaecker; JL Hopper; DR Barnes; KA Phillips; TM Mooij; MJ Roos-Blom; S Jervis; FE van Leeuwen; RL Milne; N Andrieu; DE Goldgar; MB Terry; MA Rookus; DF Easton; AC Antoniou; L McGuffog; DG Evans; D Barrowdale; D Frost; J Adlard; KR Ong; L Izatt; M Tischkowitz; R Eeles; R Davidson; S Hodgson; S Ellis; C Nogues; C Lasset; D Stoppa-Lyonnet; JP Fricker; L Faivre; P Berthet; MJ Hooning; LE van der Kolk; CM Kets; MA Adank; EM John; WK Chung; IL Andrulis; M Southey; MB Daly; SS Buys; A Osorio; C Engel; K Kast; RK Schmutzler; T Caldes; A Jakubowska; J Simard; ML Friedlander; SA McLachlan; E Machackova; L Foretova; YY Tan; CF Singer; E Olah; AM Gerdes; B Arver; H Olsson

Journal article

Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

KB Kuchenbaecker, JL Hopper, DR Barnes, KA Phillips, TM Mooij, MJ Roos-Blom, S Jervis, FE van Leeuwen, RL Milne, N Andrieu, DE Goldgar, MB Terry, MA Rookus, DF Easton, AC Antoniou, L McGuffog, DG Evans, D Barrowdale, D Frost, J Adlard Show all

JAMA | AMER MEDICAL ASSOC | Published : 2017

DOI: 10.1001/jama.2017.7112

Abstract

IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. OBJECTIVES To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 6036 BRCA1 and 3820 BRCA2 female carriers (5046 unaffected and 4810 with breast or ovarian cancer or both at baseline) recruited in 1997-2011 through the International BRCA1/2 Carrier Cohort Study, the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for Research into Familial Breast..

View full abstract